Quantcast

Industry news that matters to you.  Learn more

Archives for March 2012

Biology Researcher on the Verge of a Technological Breakthrough in Drug Creation Process

New technology being developed at Florida State University could significantly decrease the cost of drug discovery, potentially leading to increased access to high-quality health care and cancer patients receiving personalized chemotherapy treatments.

Foundation of UMDNJ Receives Grand Challenges Tuberculosis Biomarkers Grant

The Foundation of UMDNJ, an affiliate of New Jersey Health Foundation, has received a tuberculosis (TB) biomarkers grant through the Bill & Melinda Gates Foundation’s Grand Challenges in Global Health program, an initiative which seeks to overcome persistent bottlenecks in creating new tools that can radically improve health in the developing world.

Biomarkers: New Tools of Modern Medicine

Over the last few decades there has been an explosion in the discovery of biomarkers for diagnosis, disease monitoring, and prognostic evaluation. In the April issue of Translational Research, entitled “Biomarkers: New Tools of Modern Medicine,” an international group of medical experts explores the promise and challenges of biomarker discovery and highlights the latest advances in the use of biomarkers in various diseases.

Quest Diagnostics Launches First Molecular Test for Kidney Organ Transplant Rejection

Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic testing, information and services, today announced the availability of the industry’s first molecular blood test for identifying renal (kidney) organ-transplant rejection. The Renal Transplant Monitoring laboratory-developed test is designed to help physicians detect kidney failure weeks before conventional tests or clinical symptoms signify damage. The test may potentially improve patient care for kidney transplant patients while helping to lower sizeable healthcare costs associated with renal transplant failure.

AmberGen and Mass General License Two Novel Autoantigen Biomarkers for Autoimmune Liver Disease to INOVA Diagnostics

Two novel autoantigen biomarkers for the autoimmune liver disease Primary Biliary Cirrhosis (PBC), discovered by AmberGen, Inc., in collaboration with the Massachusetts General Hospital (MGH), were exclusively licensed to INOVA Diagnostics, Inc., part of the Werfen Group, and a world-leader in clinical assays for autoimmune disease. Discovery of these biomarkers was made possible by the use of AmberGen’s proprietary proteomic biomarker discovery pipeline and funded by an Advanced Technology Small Business Innovation Research (SBIR) grant to AmberGen from the National Institute of Allergy and Infectious Disease, part of the National Institutes of Health. Following the work done by AmberGen and MGH, the biomarkers where subjected to further clinical validation by INOVA.